drugset
drugset / Trial / NCT04132570

A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

NCT04132570 ↗

Phase 4 Completed 206 enrolled Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the effectiveness of intranasal budesonide aqueous spray 256 microgram (mcg)/day for treatment of rhinitis symptoms during times of high airborne pollution.

Timeline

Start
2019-10-22
Primary completion
2020-01-22
Completion
2020-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 256 ug Intranasal

Indications

rhinitis